For excerpting the "addiction module" in viruses and temperature-sensitive mutants, a rival study has emerged at Pubmed which goes into detail of the 2019-nCoV:
Receptor Recognition by Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS
Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. - PubMed - NCBI
'....What is the source of 2019-nCoV and did a key intermediate host play an important role in the current 2019-nCoV outbreak? Similar to SARS-CoV, 2019-nCoV most likely has originated from bats, given its close phylogenetic relationship with other beta-genus lineage b bat SARS-CoV (Fig. 2). Moreover, 2019-nCoV likely recognizes ACE2 (angiotensin-converting enzyme 2) from a diversity of animal species, including palm civets, as its receptor. In the case of SARS-CoV, some of its critical RBD (receptor binding domain) residues were adapted to human ACE2, while some others were adapted to civet ACE2; this type of partial viral adaptions to two host species promoted virus replication and cross-species transmission between the two host species. In the case of 2019-nCoV, however, there is no strong evidence for adaptive mutations in its critical RBM (receptor binding motif) residues that specifically promote viral binding to civet ACE2.
Hence, either palm civets were not intermediate hosts for 2019-nCoV, or they passed 2019-nCoV to humans quickly before 2019-nCoV had any chance to adapt to civet ACE2. Like SARS-CoV, 2019-nCoV will likely replicate inefficiently in mice and rats, ruling them out as intermediate hosts for 2019-nCoV. Moreover, we predict that either 2019-nCoV or laboratory mice and rats would need to be genetically engineered before a robust mouse model for 2019-nCoV would become available. Pigs, ferrets, cats and non-human primates contain largely favorable 2019-nCoV-contacting residues in their ACE2, and hence may serve as animal models or intermediate hosts for 2019-nCoV. It is worth noting that SARS-CoV was isolated from palm civets near Wuhan in 2005, and its RBD had already been well adapted to civet ACE2 (except for residue 487). Thus bats, and other wild animals in and near Wuhan should be screened for both SARS-CoV and 2019-nCoV.
These above analyses are based on the modelling of 2019-nCoV RBD/ACE2 interactions, heavily grounded in a series of atomic level structures of SARS-CoV isolated from different hosts in different years. There are certainly other factors that affect the infectivity and pathogenesis of 2019-nCoV and will need to be investigated.'